The finding of a synergy between TMZ and IMI to improve OS for IDH1 wild-type MGMT promoter-unmethylated GBM patients is remarkable in the light of the negative repercussions of TMZ on immune cells [23]. The gene discussed is MGMT; the disease is glioblastoma.